Suppr超能文献

角膜新生血管的预防;在兔身上的初步实验研究。

Prevention of Corneal Neovascularization; a Preliminary Experimental Study in Rabbits.

作者信息

Kasiri Ali, Mirdehghan Mohammad Sadegh, Farrahi Fereydoun, Ostadian Farshad, Feghhi Mostafa, Ghomi Mehdi Reza, Mohammad Jafari Aram, Mahdian Rad Atefeh, Kasiri Niusha

机构信息

Department of Ophthalmology, Faculty of Medicine, Infectious Ophthalmic Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Medical Student, Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran.

出版信息

Med Hypothesis Discov Innov Ophthalmol. 2020;9(1):47-55. Epub 2020 Jan 1.

Abstract

The purpose of this study was to compare the effects of propranolol, timolol and bevacizumab with betamethasone to prevent corneal neovascularization (CNV) in rabbits. This study was performed on 28 male rabbits. CNV was induced by three 7-0 silk sutures 2 mm long and 1 mm distal to the limbus. Animals were randomly divided into 4 groups of propranolol + betamethasone, timolol + betamethasone and bevacizumab + betamethasone and betamethasone alone. Eye drops were started from the first day of study. On 7, 14, 21, 28, 35 and 42 days, vascular progression, time of neovascularization and vascular area were evaluated and compared with the control group (betamethasone alone). There was a significant reduction in the area of ​​neovascularization in the timolol and bevacizumab groups compared to the control group (P-value = 0.05, P=0.047, respectively). Also, regarding vascular progression, there was a significant decrease in the timolol and bevacizumab groups (P-value = 0.014, P=0.002, respectively). Regarding delayed onset of neovascularization, there was a significant difference in the timolol and bevacizumab group in rabbits (P-value = 0.04, P=0.00, respectively). In conclusion, the use of timolol and bevacizumab drops besides betamethasone can delay neovascularization and decrease the length of corneal vascularization in rabbits.

摘要

本研究的目的是比较普萘洛尔、噻吗洛尔和贝伐单抗与倍他米松对预防兔角膜新生血管化(CNV)的效果。本研究选取了28只雄性兔进行。通过在角膜缘远端2mm处用三根2mm长的7-0丝线诱导产生CNV。动物被随机分为四组:普萘洛尔+倍他米松组、噻吗洛尔+倍他米松组、贝伐单抗+倍他米松组和单独使用倍他米松组。从研究第一天开始滴眼药水。在第7、14、21、28、35和42天,评估血管进展、新生血管化时间和血管面积,并与对照组(单独使用倍他米松组)进行比较。与对照组相比,噻吗洛尔组和贝伐单抗组的新生血管化面积显著减少(P值分别为0.05和0.047)。此外,关于血管进展,噻吗洛尔组和贝伐单抗组有显著下降(P值分别为0.014和0.002)。关于新生血管化延迟发生,噻吗洛尔组和贝伐单抗组在兔中存在显著差异(P值分别为0.04和0.00)。总之,除倍他米松外,使用噻吗洛尔和贝伐单抗滴眼液可延迟兔的新生血管化并减少角膜血管化的长度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8950/6969563/d15ec8cbf86f/mehdiophth-9-047-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验